- Previous Close
0.1250 - Open
0.1289 - Bid 0.1200 x --
- Ask 0.1290 x --
- Day's Range
0.1289 - 0.1290 - 52 Week Range
0.0980 - 2.1900 - Volume
11,110 - Avg. Volume
3,839,577 - Market Cap (intraday)
5.837M - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2700 - Earnings Date Apr 14, 2025 - Apr 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
nkgenbiotech.comRecent News: NKGN
View More
Performance Overview: NKGN
Trailing total returns as of 4/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NKGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NKGN
View MoreValuation Measures
Market Cap
5.21M
Enterprise Value
35.94M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-97.34%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-48.48M
Diluted EPS (ttm)
-2.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
8k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-31.33M